Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesGlatiramer acetate for multiple sclerosisTherapy with glatiramer acetate for multiple sclerosisGlatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosisGlatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of actionDevelopment of oral immunomodulatory agents in the management of multiple sclerosisMRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment.The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.Imaging of multiple sclerosis: role in neurotherapeutics.Magnetic resonance imaging monitoring of multiple sclerosis lesion evolution.MRI to monitor treatment efficacy in multiple sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Glatiramer acetate: evidence for a dual mechanism of action.Multiple sclerosis lesions: insights from imaging techniques.Black holes in multiple sclerosis: definition, evolution, and clinical correlations.Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair.Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Neuroimaging in multiple sclerosis: neurotherapeutic implications.Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration.Multiple sclerosis trial designs for the 21st century: building on recent lessons.Disease modifying agents for multiple sclerosis.Multiple sclerosis imaging: recent advances.Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate.Interferon β-1b and glatiramer acetate effects on permanent black hole evolutionGlatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.Magnetic resonance imaging of multiple sclerosis.Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.On the horizon: possible neuroprotective role for glatiramer acetate.Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.Combination therapy in multiple sclerosis.Glatiramer acetate in multiple sclerosis.Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.Glatiramer acetate therapy for multiple sclerosis: a review.
P2860
Q22241472-87FF1472-3381-477B-AA21-DDDE120BEEF8Q24235498-A9020266-DAB9-4F76-A9E7-AF83DFAC1A3BQ24247704-260DA953-2955-42AC-9058-12B2C85443FDQ28289819-071C2F9D-90E6-434E-B7B1-A2B240328319Q28308287-065B5B91-8CF9-4209-952D-C7A6315A1FA0Q28388704-8C99DCE4-D55C-4515-AA5B-059274630C03Q30798662-16962970-B9F8-475D-A75C-545CA8E6DC61Q30953733-C80999E8-E0E9-4B4D-91AE-9DCAEB9DD33BQ30983016-6369307A-405B-4296-97C0-6D206448BBB6Q30989935-2A7CB580-F4C4-40EC-8A93-4D622777DB92Q31027948-C133A1AA-39EE-4B55-AEF4-94B4A8C1E7D7Q31108872-6854B64E-FF56-4876-BCBE-DF41389721DBQ31160866-AC58B1F1-62F8-4832-8C82-9B4DA8310FD9Q33289264-D3E14961-AD4E-4CD3-B57C-DA713E14E913Q33345291-797BE04E-DA12-4C1D-A2FE-E2B262FEDA4BQ33505423-C1BC11C6-F0E5-486A-8209-D8BFD0715464Q33517838-2D230794-9106-46FE-9025-2233F917FABCQ33610240-BF32535E-53AA-4D8E-9619-4FE1DC3EBB03Q33634866-F1D1AA0F-06D4-44D4-823A-75846CA8364EQ33806032-D99F518F-66B6-4875-A0AC-64CBE9E8EA76Q34003724-BC7729F6-8201-4716-9031-541F9A28AA73Q34090086-7D9F2B38-DCBB-4C83-8608-B619B4BFBCF3Q34303664-755D170C-5931-43B9-BD04-E8ED24C1E4D9Q34463581-38961651-F8D3-4F5D-B9F5-3E8096BED6D0Q34508451-A5E47BFF-3DB8-4294-9EAD-992B033EF36EQ34522015-87A9D6CB-C5A4-4F1E-A998-8183D888B554Q34590775-15938203-CEF0-4FFD-B473-19161AF49FDCQ34705686-E02C9E26-CA31-4D76-A39F-A95E86B634A6Q34743156-D8657999-B2FF-4356-88D5-28E15343EE6BQ34852971-CB7DDF3A-7137-446E-9DE6-077E14343AD3Q34965696-AD90517F-8635-49C2-87B4-4592D9A01A26Q35008641-DA060D09-44D5-4132-ADBA-B737FD7ACF7EQ35276622-DB0F3404-5CA3-4642-A2D6-A55341197856Q35295564-F7AEC9FD-8C68-4B6E-92AE-2295FA732CBDQ35818185-97F9CB3E-CD55-4870-86BF-3D09B2FCA5A1Q35937975-03B55109-6163-476C-B85C-BB592DE38A6DQ36113050-7BAF4B55-DC6A-481B-BD53-C3D5D3C2F42CQ36198583-0C0592F1-BFF5-42B8-8964-7C671A096805Q36419566-F458A779-85B3-409A-A23F-38943A71A480Q36662903-00E674CF-339A-4F96-B738-E17F2012DC06
P2860
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
@en
type
label
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
@en
prefLabel
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
@en
P2093
P356
P1433
P1476
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
@en
P2093
Eurpoean/Canadian Glatiramer Acetate Study Group
J S Wolinsky
M P Sormani
P304
P356
10.1212/WNL.57.4.731
P407
P577
2001-08-01T00:00:00Z